Claims

1) A pharmaceutical preparation characterized by a content of at least one compound of general formula (I)

$$Pd(S_2COR)_2$$

wherein R is a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.

2) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R is a straight-chain C1-14 alkyl residue or a C3-14 cycloalkyl residue each.

3) The pharmaceutical preparation according to claim 1 or 2, in the compound of formula (I) wherein R is CH_3CH_2, isopropyl, CH_2CH_2OH, $CH_2CH_2CH_2OH$ or $CH_2(CH_2)_2CH_2OH$.

4) The pharmaceutical preparation according to any one of claims 1 to 3, wherein the compound of formula (I) is Bis(O-cyclohexyl-dithiocarbonato)palladium(II), Bis-isopropyl-dithiocarbonato)palladium(II), Bis(O-ethyl-dithiocarbonato)palladium(II), Bis(O-(2-methyl)-butyl-dithiocarbonato)palladium(II), Bis(O-butyl-dithiocarbonato)-palladium(II),Bis(O-hexyl-dithiocarbonato)palladium(II) or Bis(O-methyl-dithiocarbonato)palladium(II).

5) The pharmaceutical preparation according to any one of claims 1 to 4, comprising additionally an immunosuppressive

compound selected from the group consisting of cyclosporine, rapamycin, 15-deoxyspergualine, OKT3 and azathioprine.

6) The pharmaceutical preparation according to any one of claims 1 to 4, comprising additionally cytokines, interferon or further cytostatic agents.

7) The pharmaceutical preparation according to any one of claims 1 to 6, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer or anti-autoimmunic agent.

8) The pharmaceutical preparation according to any one of claims 1 to 7, further comprising a pharmaceutically compatible inert carrier or a diluent.

9) Use of a pharmaceutical preparation according to any one of claims 1 to 8 for treating a cancerous disease.

10) Use according to claim 9, wherein the cancerous disease is the parvocellular bronchial carcinoma or colorectal carcinoma.

11) Use of a pharmaceutical preparation according to any one of claims 1 to 8 for treating an autoimmune disease.

12) A process for the production of a pharmaceutical preparation according to any one of claims 1 to 8, characterized in that the compound according to formula (I) is mixed with a pharmaceutically compatible carrier or diluent.